» Articles » PMID: 29344025

Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity?

Overview
Journal Cardiorenal Med
Publisher Karger
Date 2018 Jan 19
PMID 29344025
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Insulin resistance is a central component of the metabolic dysregulation observed in obesity, which puts one at risk for the development of type 2 diabetes and complications related to diabetes such as chronic kidney disease. Insulin resistance and compensatory hyperinsulinemia place one at risk for other risk factors such as dyslipidemia, hypertension, and proteinuria, e.g., development of kidney disease. Our traditional view of insulin actions focuses on insulin-sensitive tissues such as skeletal muscle, liver, adipose tissue, and the pancreas. However, insulin also has distinct actions in kidney tissue that regulate growth, hypertrophy, as well as microcirculatory and fibrotic pathways which, in turn, impact glomerular filtration, including that governed by tubuloglomerular feedback. However, it is often difficult to discern the distinct effects of excess circulating insulin and impaired insulin actions, as exist in the insulin resistance individual, from the associated effects of obesity or elevated systolic blood pressure on the development and progression of kidney disease over time. Therefore, we review the experimental and clinical evidence for the distinct impact of insulin resistance on kidney function and disease.

Citing Articles

Higher triglyceride-glucose index is associated with severe proteinuria and decreased renal function in patients with primary membranous nephropathy.

Gao Y, Wang Z, Deng Z, Wang Y BMC Nephrol. 2025; 26(1):114.

PMID: 40045226 PMC: 11884001. DOI: 10.1186/s12882-025-04022-5.


Evaluation of circulating glypican 4 as a novel biomarker in disease - A comprehensive review.

Muendlein A, Leiherer A, Drexel H J Mol Med (Berl). 2025; .

PMID: 39961831 DOI: 10.1007/s00109-025-02520-5.


Predictive value of TG/HDL-C and GFR-adjusted uric acid levels on cardiovascular mortality: the URRAH study.

Russo E, Viazzi F, Pontremoli R, Angeli F, Barbagallo C, Berardino B Lipids Health Dis. 2025; 24(1):21.

PMID: 39856749 PMC: 11760098. DOI: 10.1186/s12944-025-02440-w.


Associations between non-insulin-based insulin resistance indices and diabetic nephropathy in patients with diabetes mellitus in US adults: a cross-sectional study of NHANES 1999-2018.

Zhang F, Han Y, Mao Y, Li W Front Endocrinol (Lausanne). 2024; 15:1458521.

PMID: 39720248 PMC: 11666371. DOI: 10.3389/fendo.2024.1458521.


Relationship between METS-IR and ABSI index and the prevalence of nocturia: a cross-sectional analysis from the 2005-2020 NHANES data.

Xue F, Zhou Y Sci Rep. 2024; 14(1):29971.

PMID: 39623038 PMC: 11611885. DOI: 10.1038/s41598-024-81721-3.


References
1.
Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C, Takishita S . Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004; 65(5):1870-6. DOI: 10.1111/j.1523-1755.2004.00582.x. View

2.
Susic D, Frohlich E . Hyperuricemia: A Biomarker of Renal Hemodynamic Impairment. Cardiorenal Med. 2015; 5(3):175-82. PMC: 4478304. DOI: 10.1159/000381317. View

3.
Chen J, Muntner P, Hamm L, Fonseca V, Batuman V, Whelton P . Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. J Am Soc Nephrol. 2003; 14(2):469-77. DOI: 10.1097/01.asn.0000046029.53933.09. View

4.
Jindal A, Brietzke S, Sowers J . Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors. Cardiorenal Med. 2013; 2(4):314-327. PMC: 3551409. DOI: 10.1159/000343803. View

5.
Wisse B . The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004; 15(11):2792-800. DOI: 10.1097/01.ASN.0000141966.69934.21. View